We know that CYP1A2 metabolises other xenobiotic substrates other than caffeine and although neither of the SNPs used in this analysis were found to associate with blood metabolites (other than caffeine) at genome wide significance level,16 we cannot rule out the possibility that associations with prostate cancer occur via metabolism of these other compounds. The gene discussed is CYP1A2; the disease is prostate cancer.